[{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz to initiate phase III clinical trial of centhaquine","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide Significantly Improved Clinical Outcome in Patients with Acute Cerebral Ischemic Stroke When Compared to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sovateltide (PMZ-1620), a First-in-Class Investigational Product, Shows Promise to Slow Down the Progression of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Submits Investigational New Drug Application to India Central Drugs Standard Control Organization for a Phase II clinical trial of Sovateltide (PMZ-1620) in Hypoxic-ischemic Encephalopathy in Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmazz Inc. and Sun Pharma Enter into Licensing Agreement for Introducing Tyvalzi\u2122 (sovateltide) in India","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to Conduct a Phase II Clinical Trial of Sovateltide (PMZ-1620) in Hypoxic-Ischemic Encephalopathy in Neonates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide\u2019s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Phase III Trial Results Demonstrating Sovateltide's Efficacy to Treat Acute Cerebral Ischemic Stroke Presented at The International Stroke Conference 2023","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 Clinical Trial of Sovateltide for The Treatment of Acute Cerebral Ischemic Stroke Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Sovateltide
Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the same indication.
Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ischemic stroke patients.
Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.
PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemic stroke.
PMZ-1620 having Sovateltide as API, is the Company’s endothelin-B receptor agonist that is also in a Phase III trial for the treatment of cerebral ischemic stroke. In clinical trials, subjects will receive either three intravenous doses of sovateltide, 0.3 ug/kg or a placebo.
The interim analysis of data indicates a numerical difference indicative of a potential beneficial effect of sovateltide in Alzheimer's disease patients with late early to moderate stage disease.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
